JSR-LIFE-SCIENCES
JSR Announces Acquisition of Crown Biosciences International
JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities, and ability to develop impactful solutions for pharma.
As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence. Upon completion of the acquisition, JSR Life Sciences’ will enjoy a full suite of integrated capabilities that extend from pure research, to drug discovery, diagnostics development, cell line development and process development, through to GMP manufacturing.
“We are positioning to be the clear choice for innovation-driven strategic partnerships,” said Eric R. Johnson, President of JSR’s Life Sciences Division. “CrownBio, and its science-rich approach, is an ideal fit to support that goal. We’re bringing together innovative competencies that will lead to better solutions for pharma and improve their ability to take therapeutics to the market.”
As focus on personalized medicine continues to increase, CROs are turning into scientific leaders. Translational platforms, bioinformatics and modeling capabilities, like CrownBio’s patient-derived xenograft (PDX) models, are becoming fundamentally important to the development and commercialization of diagnostics and therapeutics. JSR’s forecast, based on consultation with CrownBio’s management team, is for the company to realize Revenue and EBITDA margin of 90 and 20 M USD respectively in 2018, with the understanding that such projected financial information may vary from actual results.
JSR has had extensive M&A activity in recent years. The 2015 majority interest acquisitions of contract development and manufacturing organization KBI Biopharma, Inc. and MBL Corporation, and the 2017 acquisition of mammalian cell line development pioneer Selexis SA, combine to be a strong technology engine for innovation.
JSR envisions that CrownBio’s development capabilities will enhance the contribution of JKiC, the company’s Japan-based industry-academia-medicine collaboration hub, by providing the tools and expertise to translate leading-edge research into tomorrow’s medicines.
About Crown Bioscience
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
About JSR Corporation
JSR Corporation is a multinational company with research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials. JSR Corporation conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical & Biological Laboratories Co. Ltd, KBI Biopharma, Inc. and Selexis SA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171220005165/en/
Contact:
JSR Life Sciences
Missy Bindseil, 1-830-237-9527
mbindseil@jsrlifesciences.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PSE20.4.2018 17:15 | pressemeddelelse
PSE: APM Forum 2018 Focus on Digitalisation for the Process Industries
APERTA20.4.2018 16:03 | pressemeddelelse
Aperta Provides Electronic Funds Transfer (EFT) in Cayman Islands
SECO-SPA20.4.2018 15:41 | pressemeddelelse
FII Tech Growth Invests in SECO
SCHLUMBERGER-LIMITED20.4.2018 13:07 | pressemeddelelse
Schlumberger Announces First-Quarter 2018 Results
MA-BIOGEN20.4.2018 12:32 | pressemeddelelse
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
AZ-VERSUM-MATERIALS19.4.2018 22:17 | pressemeddelelse
Versum Materials Celebrates the Grand Opening of Its Research and Development Facility in Hometown, PA
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.
Besøg vores nyhedsrum